Abstract
Chemotherapy with oxazaphosphorines, such as ifosfamide, is often limited by unacceptable urotoxicity. Without uroprotection hemorrhagic cystitis becomes doselimiting. Mesna, a thiol compound, is a drug able to bind the toxic metabolites, forming nontoxic compounds in the urine. A total of 122 patients were enrolled in this study and 228 chemotherapy cycles with an ifosfamide-containing regimen were performed (225 evaluable). Mesna was given at the same total dose as the ifosfamide in all arms. On arm A, mesna was given i. v. in equal doses 15 min before and 4 h and 8 h following the ifosfamide dose. On arm B, mesna was given in three equivalent doses 15 min before (i.v.) and 4 h (i.v.) and 8 h (p.o., double dose) following ifosfamide. On arm C, mesna was given i.v. intwo equal doses given 15 min before and 4 h following. The incidence of urotoxicity was very low (lower than 15%) in the three arms, 0% in A, 1.36% in B and 2.70% in C. All three arms were equally efficient. Schedule C was considered superior to the others, since it was equally effective, simpler and more convenient.
Similar content being viewed by others
References
Allen LM, Creaven PJ, Nelson RL (1976) Studies on the human pharmacokinetics of isophosphamide. Cancer Treat Rep 60: 451–458
andriole GL, Sandlund JT, Miser JS (1987) The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy. J Clin Oncol 5: 799–803
Brock N, Pohl J, Stekar J (1981) Studies on the urotoxicity of oxazaphosphorines and its prevention. 2. Comparative study on the uroprotective efficacy of thiols and other sulfur compounds. Eur J Cancer Clin Oncol 17: 1155–1163
Bryant BM, Jarman M, Ford HT (1980) Prevention of isophosphamide-induced urothelial toxicity with 2-mercaptoethane sulphonate sodium (mesnum) in patients with advanced carcinoma. Lancet 2: 657–659
Cabanillas F (1990) Advances in ifosfamide chemotherapy. A panel discussion. Semin Oncol 17 [Suppl 4]: 74–79
Czownicki Z, Utratcka-Hutka B (1980) Clinical studies with uromitexan — an antidote against urotoxicity of Holoxan. Preliminary results. Nowotwory 30:1377–383
Legha S, Papadopoulos N, Plager C (1990) A comparative evaluation of the uroprotective effect of mercaptoethane sulfonate (mesna) andN-acetylcysteine (NAC) in sarcoma patients treated with ifosfamide. Proc Am Soc Clin Oncol 9: 311, abstract 1205
Munshi NC, Loehrer PJ, Williams SD (1989) Comparison ofN-acetylcysteine (NAC) and mesna as uroprotective agents in ifosfamide combination therapy. Proc Am Soc Clin Oncol 8: 130, abstract 506
Sarosy G (1989) Ifosfamide-pharmacologic overview. Semin Oncol 16 [Suppl 3]: 2–8
Scheef W, Klein HO, Brock N (1979) Controlled clinical studies with an antidote against the urotoxicity oxazaphosphorines: preliminary results. Cancer Treat Rep 63: 501–505
Shaw IC, Graham MI (1987) Mesna — a short review. Cancer Treat Rev 14: 67–86
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Katz, A., Epelman, S., Anelli, A. et al. A prospective randomized evaluation of three schedules of mesna administration in patients receiving an ifosfamide-containing chemotherapy regimen: sustained efficiency and simplified administration. J Cancer Res Clin Oncol 121, 128–131 (1995). https://doi.org/10.1007/BF01202226
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01202226